Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious ...

BTIG analyst Julian Harrison has maintained their bullish stance on SYRE stock, giving a Buy rating on January 14.Invest with Confidence: ...

Coya Therapeutics, Inc. (NASDAQ:COYA) announced the expansion of its investigational pipeline and advancement of COYA 303 for ...

Celldex Therapeutics , Inc. (NASDAQ:CLDX), a biopharmaceutical company with a market capitalization of $1.6 billion focused on developing innovative therapies for challenging diseases, has been making ...

Analyst Arthur He CFA of H.C. Wainwright maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), retaining the price target of $6.50. Discover outperforming stocks and invest smarter ...

NDAQ:HOTH) Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications ...

Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

The Global Ophthalmic Disease Therapeutics market showcased growth ... healthcare infrastructure are anticipated to propel market expansion. The rising incidence of lifestyle-related eye diseases ...

The global cancer therapeutics market is on an exponential growth trajectory, driven by advancements in treatment methodologies, increased investment in cancer research, and the rising global burden ...

Amicus Therapeutics reports 2024 revenue of $528M, a 32% increase, with positive 2025 growth projections for key therapies. 2024 total revenue reached $528.5 million, marking a significant year ...

Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...

Data from expansion arms in Phase 1/1b clinical trial evaluating ... Jan. 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or ...